The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.

India is showing real commitment to realize its vision of becoming a “pharmacy of the world” by implementing policies and ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...